Trimuvira Corporate Presentation – 4th Quarter 2023

October 31, 2023

Triumvira

First in class engineered T cells for safer, more efficacious and durable therapies in solid tumors

Triumvira’s proprietary TAC technology utilizes a novel mechanism of action (MoA) with the potential to enhance the immune response of millions of patients with difficult-to-treat tumors.

For more information, please view our Corporate Presentation linked below.

Triumvira Corporate Presentation – 1.7mb PDF